RT Journal Article
SR Electronic
T1 Chemoprophylaxis of COVID-19 with hydroxychloroquine - a study of health care workers attitude, adherence to regime and side effects
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.11.20126359
DO 10.1101/2020.06.11.20126359
A1 Bhattacharyya, Debajyoti
A1 Raizada, Neeraj
A1 Nagappa, Bharathnag
A1 Tomar, Arvind
A1 Maurya, Prateek
A1 Chaudhary, Ashok
A1 George, Mini
A1 Katiyal, Deepty
A1 Rajora, Srishti
A1 Singh, Nikky
YR 2020
UL http://medrxiv.org/content/early/2020/06/12/2020.06.11.20126359.abstract
AB Background There are apprehensions amongst healthcare worker (HCWs) about COVID-19. The HCWs have been given hydroxychloroquine (HCQ) chemoprophylaxis for seven weeks as per Government of India guidelines.Objectives To assess the apprehensions amongst HCWs about COVID-19 and to document accessibility, adherence and side effects related to HCQ prophylaxis in HCWs.Methods A longitudinal follow up study was conducted in a tertiary care hospital. HCQ was given in the dose of 400 mg twice on day one, and then 400 mg weekly for seven weeks. 391 HCWs were interviewed using semi structured questionnaire.Results 62.2% HCWs expressed perceived danger posted by COVID-19 infection. Doctors (54%) showed least acceptance and paramedics (88%) showed highest acceptance to chemoprophylaxis. 17.5% participants developed at least one of the side effects to HCQ. Females and nursing profession were significantly associated with adverse effects. Common side effects were gastro-intestinal symptoms, headache and abnormal mood change. Most of these were mild, not requiring any intervention. Gender, professions and perceived threat of COVID-19 were significantly associated with acceptance and adherence to HCQ prophylaxis.Conclusion Two third of HCWs had perceived danger due to COVID-19. Three fourth of the HCWs accepted chemoprophylaxis and four out of five who accepted had complete adherence to prophylaxis schedule. One out of five had developed at least one of side effects; however, most of these were mild not requiring any intervention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding have been received for this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institute of Liver and Biliary Sciences, New Delhi, India granted ethical approval to carry out the study 118 within its facilities (ethical application ref. F.37/(1)/9/ILBS/DOA/2020/20217/262). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data referred to in the manuscript is available at: https://drive.google.com/drive/folders/1PCazhITB8xjCT6fp_iHvjEHerDypmN9H